Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VZV modRNA Vaccine in Healthy Individuals
NCT05703607Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of varicella zoster virus modRNA in herpes zoster (HZ) (14 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting local reactions, Percentage of participants reporting systemic events and 6 more. Started Jan 2023; status: terminated.
02
Drugs
varicella zoster virus modRNA
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05703607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703607.